IP Library Granted Patent US 10,576,067
Granted Patent B2
US 10,576,067 · App. 16/541,665 · Granted Mar 3, 2020

Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof

Inventors: Gene H. Zaid (Sterling, KS); Thomas W. Burgoyne (Lake Zurich, IL)
Assignee: Ankh Life Sciences Limited
A61K31/437A61K31/11A61K31/12A61K31/4375A61K45/06A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,576,067
App. No.
16/541,665
Granted
Mar 3, 2020
Kind
B2
Abstract

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Claims (7)

1. A method of killing or inhibiting the growth of cancer cells selected from the group consisting of lung and lymphoma cells, comprising the step of administering to a patient a composition comprising a quantity of a harmine component selected from the group consisting of harmine, and the esters, metal complexes, and pharmaceutically acceptable salts thereof, with a quantity of a isovanillin component selected from the group consisting of vanillin, isovanillin, and mixtures thereof, and the esters, metal complexes, and pharmaceutically acceptable salts of the foregoing, said harmine component and said isovanillin component being selected and present in amounts to provide anti-cancer synergy for the composition.

2. The method of claim 1 , including the step of co-administering a composition in accordance with said composition together with one or more other chemotherapeutic agents.

3. The method of claim 1 , said administering step comprising oral, rectal, nasal, ophthalmic, parenteral, cutaneous, and subcutaneous administration.

4. The method of claim 1 , including the step of administering said composition at a level of from about 5-2000 mg per day.

5. The method of claim 1 , including the step of administering said composition as a single administration per day, or multiple administrations per day.

6. The method of claim 1 , said composition exhibiting anti-cancer activity against lung cells.

7. The method of claim 6 , said composition exhibiting anti-cancer activity against lymphoma cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2019
From: IONS PHARMACEUTICAL S.A R.L.
To: ANKH LIFE SCIENCES LIMITED
Reel/Frame 050064/0991 →
Continuity (11)
Continuation 16213774 · Dec 7, 2018
Continuation 15826101 · Nov 29, 2017
Continuation 15337987 · Oct 28, 2016
Continuation PCTIB2016000723 · Apr 20, 2016
Continuation In Part PCTUS2015055968 · Oct 16, 2015
Continuation In Part 14721011 · May 26, 2015
Continuation In Part 14721011
Provisional Application 62184051 · Jun 24, 2015
Provisional Application 62161090 · May 13, 2015
Provisional Application 62066686 · Oct 21, 2014
Related Publication 20200000779A1 · Jan 2, 2020